ANTEROGEN.CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14,330 KRW | +0.63% |
|
+0.63% | -16.15% |
| Sales 2022 | 6.59B 4.79M 6.54M | Sales 2023 | 6.5B 4.73M 6.45M | Capitalization | 166B 121M 165M |
|---|---|---|---|---|---|
| Net income 2022 | -6.84B -4.97M -6.79M | Net income 2023 | -2.84B -2.07M -2.82M | EV / Sales 2022 | 15.1 x |
| Net cash position 2022 | 43.26B 31.45M 42.95M | Net cash position 2023 | 40.59B 29.51M 40.31M | EV / Sales 2023 | 19.3 x |
| P/E ratio 2022 |
-20.8
x | P/E ratio 2023 |
-58.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 77.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.63% | ||
| 1 week | +0.63% | ||
| Current month | -0.28% | ||
| 1 month | -0.69% | ||
| 3 months | +0.77% | ||
| 6 months | +12.30% | ||
| Current year | -16.15% |
1 week
14 170.00
14 650.00
1 month
13 800.0019 150.00
Current year
13 200.0019 150.00
1 year
12 300.0019 820.00
3 years
12 300.00101 500.00
5 years
12 300.00101 500.00
10 years
12 300.00238 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mi-Hyung Kim
CEO | Chief Executive Officer | 55 | 04-02-29 |
Sung-Koo Lee
CEO | Chief Executive Officer | 69 | 00-03-15 |
In-Ok Kim
CTO | Chief Tech/Sci/R&D Officer | 48 | 02-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Koo Lee
CEO | Chief Executive Officer | 69 | 00-03-15 |
Mi-Hyung Kim
CEO | Chief Executive Officer | 55 | 04-02-29 |
Sang-Soo Lee
BRD | Director/Board Member | 70 | 17-02-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 14,330 | +0.63% | 11,558 |
| 24-04-25 | 14,240 | -1.32% | 18,633 |
| 24-04-24 | 14,430 | +0.42% | 19,888 |
| 24-04-23 | 14,370 | -0.21% | 11,951 |
| 24-04-22 | 14,400 | +1.12% | 22,198 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -16.15% | 101M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- A065660 Stock
